{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:53Z","timestamp":1792788293380,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Laboratorios Sophia, S.A. de C.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic macular edema (DME) is a leading cause of vision impairment. This study evaluated the effects of multiple anti-VEGF intravitreal injections, including a novel anti-VEGF PRO-169, on best-corrected visual acuity (BCVA) and central macular thickness (CMT) in Latino patients with DME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multicenter, drug-agnostic interim analysis. Patients were randomized 1:1 to receive monthly injections for four months after a pro re nata intravitreal injection of either PRO-169 or ranibizumab over a one-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 278 eyes with DME were analyzed. The average age of the participants was 62.1\u2009\u00b1\u20097.4 years, with diabetes diagnosed at an average of 16.7\u2009\u00b1\u20098.4 years and DME detected 1.2\u2009\u00b1\u20091.6 years later. By week 48, patients with an initial BCVA letter score of &lt;\u200969 experienced a gain of 13.1\u2009\u00b1\u200910.4 letters, with an injection frequency of 34.5\u2009\u00b1\u20096.9 days per injection. The group showed a reduction in CMT of -127\u2009\u00b1\u2009153\u00a0\u03bcm, compared to a -82.2\u2009\u00b1\u200982.1\u00a0\u03bcm reduction in those with an initial BCVA between 69 and 78 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016). Additionally, 49% of patients with an initial score\u2009&lt;\u200969 letters improved their visual acuity to 20\/40 or better, and 41.5% gained 15 or more letters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This interim analysis indicates the potential effectiveness of the anti-VEGF agents PRO-169 and ranibizumab, especially for patients with initial visual acuity\u2009&lt;\u200969 letters. The final analysis will be essential for verifying the efficacy and safety of PRO-169. This study provides solid evidence to support ophthalmologists treating Latino patients with DME and likely improves patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT05217680 (clinicaltrials.gov).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00719-9","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T07:58:57Z","timestamp":1754035137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["One-year results of visual response following intravitreal novel anti-VEGF injection for diabetic macular edema in a Latino population"],"prefix":"10.1186","volume":"11","author":[{"given":"Guillermo","family":"Salcedo-Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Garcia-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Palacio-Pastrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Gasc\u00f3n-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aureliano","family":"Moreno-Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Olvera-Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"12","key":"719_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.oret.2023.07.015","volume":"7","author":"AJ Yu","year":"2023","unstructured":"Yu AJ, Masalkhi M, Brown R, Chen B, Chhablani J. Racial and ethnic distribution in diabetic macular edema clinical trials in the united States (2002\u20132021). Ophthalmol Retina. 2023;7(12):1035\u201341.","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"719_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"719_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"issue":"7","key":"719_CR4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ophtha.2004.03.002","volume":"111","author":"R Varma","year":"2004","unstructured":"Varma R, Torres M, Pe\u00f1a F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos. Ophthalmology. 2004;111(7):1298\u2013306.","journal-title":"Ophthalmology"},{"issue":"5","key":"719_CR5","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s40123-023-00787-w","volume":"12","author":"JM Torres-Arellano","year":"2023","unstructured":"Torres-Arellano JM, Tornero-Jimenez A, S\u00e1nchez-R\u00edos A, Olvera-Monta\u00f1o O, Mu\u00f1oz-Villegas P. Evaluation of the relationship between diabetic macular edema and renal function in a Latino population. Ophthalmol Ther. 2023;12(5):2745\u201355.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"719_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","volume":"140","author":"EA Lundeen","year":"2022","unstructured":"Lundeen EA, Andes LJ, Rein DB, Wittenborn JS, Erdem E, Gu Q, et al. Trends in prevalence and treatment of diabetic macular edema and Vision-Threatening diabetic retinopathy among medicare part B Fee-for-Service beneficiaries. JAMA Ophthalmol. 2022;140(4):345.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"719_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10900-018-0574-1","volume":"44","author":"I Marquez","year":"2019","unstructured":"Marquez I, Calman N, Crump C. A framework for addressing Diabetes-Related disparities in US Latino populations. J Community Health. 2019;44(2):412\u201322.","journal-title":"J Community Health"},{"issue":"6","key":"719_CR8","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2337\/dc21-1543","volume":"45","author":"C Cordero","year":"2022","unstructured":"Cordero C, Schneiderman N, Llabre MM, Teng Y, Daviglus ML, Cowie CC, et al. Diabetes incidence among hispanic\/latino adults in the Hispanic community health study\/study of Latinos (HCHS\/SOL). Diabetes Care. 2022;45(6):1482\u20135.","journal-title":"Diabetes Care"},{"issue":"1","key":"719_CR9","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","volume":"2","author":"TY Wong","year":"2016","unstructured":"Wong TY, Cheung CMG, Larsen M, Sharma S, Sim\u00f3 R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2(1):16012.","journal-title":"Nat Rev Dis Primers"},{"key":"719_CR10","doi-asserted-by":"crossref","unstructured":"Gurreri A, Pazzaglia A. Diabetic macular edema: state of art and intraocular pharmacological approaches. In 2020. p. 375\u201389.","DOI":"10.1007\/5584_2020_535"},{"issue":"12","key":"719_CR11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"D Browning","year":"2018","unstructured":"Browning D, Stewart M, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018;66(12):1736.","journal-title":"Indian J Ophthalmol"},{"key":"719_CR12","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ulloa A, P\u00e9rez-Peralta L, Jaime-Casas S, Jim\u00e9nez-Corona A, Rivera-De La Parra D, Graue-Hern\u00e1ndez E, et al. Risk factors associated with diabetic retinopathy with and without macular edema in recently diagnosed patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2024;17:231\u20138.","DOI":"10.2147\/DMSO.S447658"},{"issue":"21","key":"719_CR13","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cells11213362","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, et al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022;11(21):3362.","journal-title":"Cells"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016;2016:1\u201317.","journal-title":"J Diabetes Res"},{"key":"719_CR15","doi-asserted-by":"crossref","unstructured":"Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, et al. Diabetic macular edema. In 2017. p. 102\u201338.","DOI":"10.1159\/000455277"},{"issue":"6","key":"719_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000516614","volume":"244","author":"DAK Kuroiwa","year":"2021","unstructured":"Kuroiwa DAK, Malerbi FK, Regatieri CVS. New insights in resistant diabetic macular edema. Ophthalmologica. 2021;244(6):485\u201394.","journal-title":"Ophthalmologica"},{"issue":"11","key":"719_CR17","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.3390\/ijms24119591","volume":"24","author":"T Tatsumi","year":"2023","unstructured":"Tatsumi T. Current treatments for diabetic macular edema. Int J Mol Sci. 2023;24(11):9591.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"719_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","volume":"69","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic S, Lupidi M, Donati S, Astarita C, Gallinaro V, Pilotto E. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv Ophthalmol. 2024;69(6):870\u201381.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"719_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1124\/jpet.119.262956","volume":"373","author":"S Torres-Costa","year":"2020","unstructured":"Torres-Costa S, Alves Valente MC, Falc\u00e3o-Reis F, Falc\u00e3o M. Cytokines and growth factors as predictors of response to medical treatment in diabetic macular edema. J Pharmacol Exp Ther. 2020;373(3):445\u201352.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"719_CR20","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/ijms22073427","volume":"22","author":"H Noma","year":"2021","unstructured":"Noma H, Yasuda K, Shimura M. Involvement of cytokines in the pathogenesis of diabetic macular edema. Int J Mol Sci. 2021;22(7):3427.","journal-title":"Int J Mol Sci"},{"issue":"S1","key":"719_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","volume":"34","author":"WM Amoaku","year":"2020","unstructured":"Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK consensus working group. Eye. 2020;34(S1):1\u201351.","journal-title":"Eye"},{"issue":"13","key":"719_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.64.13.31","volume":"64","author":"Y Takamura","year":"2023","unstructured":"Takamura Y, Yamada Y, Morioka M, Gozawa M, Matsumura T, Inatani M. Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema. Invest Opthalmology Visual Sci. 2023;64(13):31.","journal-title":"Invest Opthalmology Visual Sci"},{"issue":"9","key":"719_CR23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-Year outcomes after initial aflibercept, bevacizumab, or Ranibizumab treatment for diabetic macular edema (Protocol T extension Study). Ophthalmology. 2020;127(9):1201\u201310.","journal-title":"Ophthalmology"},{"issue":"4","key":"719_CR24","first-page":"615","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. RESTORE Study Ophthalmol. 2011;118(4):615\u201325.","journal-title":"RESTORE Study Ophthalmol"},{"issue":"4","key":"719_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema. Ophthalmology. 2012;119(4):789\u2013801.","journal-title":"Ophthalmology"},{"issue":"11","key":"719_CR26","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal Aflibercept for diabetic macular edema. Ophthalmology. 2016;123(11):2376\u201385.","journal-title":"Ophthalmology"},{"issue":"6","key":"719_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab Treat-and-Extend for diabetic macular edema. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"11","key":"719_CR28","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of Ranibizumab in diabetic macular edema (RESOLVE Study). Diabetes Care. 2010;33(11):2399\u2013405.","journal-title":"Diabetes Care"},{"key":"719_CR29","doi-asserted-by":"publisher","first-page":"e56741","DOI":"10.2196\/56741","volume":"10","author":"K Choi","year":"2024","unstructured":"Choi K, Park SJ, Yoon H, Choi S, Mun Y, Kim S, et al. Patient-Centered economic burden of diabetic macular edema: retrospective cohort study. JMIR Public Health Surveill. 2024;10:e56741.","journal-title":"JMIR Public Health Surveill"},{"issue":"6","key":"719_CR30","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jval.2023.03.492","volume":"26","author":"D Tabano","year":"2023","unstructured":"Tabano D, Watane A, Gale R, Cox O, Garmo V, Hill S, AN INVESTIGATION OF THE ECONOMIC BURDEN OF TREATMENT FOR NAMD\/DME ON TREATMENT RECIPIENTS AND CAREGIVERS IN THE US, et al. Value Health. 2023;26(6):S94\u201394.","journal-title":"Value Health"},{"key":"719_CR31","doi-asserted-by":"publisher","unstructured":"Cheema AA, Cheema HR. Diabetic macular edema management: a review of anti-vascular endothelial growth factor (VEGF) therapies. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.52676.","DOI":"10.7759\/cureus.52676"},{"key":"719_CR32","doi-asserted-by":"crossref","unstructured":"Hertzberg SN, Moe MC, J\u00f8rstad \u00d8K, Petrovski B\u00c9, Burger E, Petrovski G. Healthcare expenditure of intravitreal anti-vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema. Acta Ophthalmol. 2022;100(8).","DOI":"10.1111\/aos.15151"},{"key":"719_CR33","doi-asserted-by":"publisher","first-page":"101711","DOI":"10.1016\/j.biologicals.2023.101711","volume":"84","author":"MG Qui\u00f1onez-Alvarado","year":"2023","unstructured":"Qui\u00f1onez-Alvarado MG, Ch\u00e1vez-Hurtado P, Caro-Palomera JC, Ni\u00f1o-Trejo OL, Jim\u00e9nez-Dolores JI, Mu\u00f1oz-Villegas P, et al. Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with bevacizumab. Biologicals. 2023;84:101711.","journal-title":"Biologicals"},{"key":"719_CR34","doi-asserted-by":"crossref","unstructured":"Olvera-Monta\u00f1o O, Baiza-Duran L, Quintana-Hau JD, Qui\u00f1onez-Alvarado MG, Zeng W, Gong L, et al. Comparing the efficacy of an anti-human VEGF-A neutralizing antibody versus bevacizumab on a laser-induced choroidal neovascularization (CNV) rhesus monkey model. Drug Des Devel Ther. 2019;13.","DOI":"10.2147\/DDDT.S219350"},{"issue":"1","key":"719_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40942-020-00235-y","volume":"6","author":"L Baiza-Dur\u00e1n","year":"2020","unstructured":"Baiza-Dur\u00e1n L, S\u00e1nchez-R\u00edos A, Gonz\u00e1lez-Bar\u00f3n J, Olvera-Monta\u00f1o O, Correa-Gallegos E, Navarro-S\u00e1nchez A, et al. Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus Ranibizumab in new Zealand white rabbits. Int J Retina Vitreous. 2020;6(1):32.","journal-title":"Int J Retina Vitreous"},{"key":"719_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2147\/JEP.S308388","volume":"13","author":"P Mu\u00f1oz-Villegas","year":"2021","unstructured":"Mu\u00f1oz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Monta\u00f1o O, Quintana-Hau JD, Baiza-Duran L. Pharmacokinetics and safety of an intravitreal humanized Anti-VEGF-A monoclonal antibody (PRO-169), a biosimilar candidate to bevacizumab. J Exp Pharmacol. 2021;13:545\u201354.","journal-title":"J Exp Pharmacol"},{"issue":"20","key":"719_CR37","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration","year":"2011","unstructured":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"issue":"6","key":"719_CR38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or Ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(6):1351\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"719_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12886-018-0978-9","volume":"18","author":"PR Merz","year":"2018","unstructured":"Merz PR, R\u00f6ckel N, Ballikaya S, Auffarth GU, Schmack I. Effects of Ranibizumab (Lucentis\u00ae) and bevacizumab (Avastin\u00ae) on human corneal endothelial cells. BMC Ophthalmol. 2018;18(1):316.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"719_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00417-020-04936-w","volume":"259","author":"S Yoshida","year":"2021","unstructured":"Yoshida S, Murakami T, Nozaki M, Suzuma K, Baba T, Hirano T, et al. Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2021;259(4):815\u201336.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"6","key":"719_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or Ranibizumab for diabetic macular oedema. Curr Opin Ophthalmol. 2017;28(6):636\u201343.","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"719_CR42","doi-asserted-by":"publisher","first-page":"e0296998","DOI":"10.1371\/journal.pone.0296998","volume":"19","author":"SA Medina-Ramirez","year":"2024","unstructured":"Medina-Ramirez SA, Soriano-Moreno DR, Tuco KG, Castro-Diaz SD, Alvarado-Villacorta R, Pacheco-Mendoza J, et al. Prevalence and incidence of diabetic retinopathy in patients with diabetes of Latin America and the caribbean: A systematic review and meta-analysis. PLoS ONE. 2024;19(4):e0296998.","journal-title":"PLoS ONE"},{"issue":"11","key":"719_CR43","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jamaophthalmol.2022.3929","volume":"140","author":"AH Kaakour","year":"2022","unstructured":"Kaakour AH, Hua HU, Rachitskaya A. Representation of race and ethnicity in randomized clinical trials of diabetic macular edema and retinal vein occlusion compared to 2010 US census data. JAMA Ophthalmol. 2022;140(11):1096.","journal-title":"JAMA Ophthalmol"},{"key":"719_CR44","doi-asserted-by":"crossref","unstructured":"Lugo SL, Cabrera A, Aschner AG, Cerezo MN, Escobar MA, Gonz\u00e1lez LG, et al. Diabetes in Latin America: prevalence, complications, and socio-economic impact. Int J Diabetes Clin Res. 2019;6(3).","DOI":"10.23937\/2377-3634\/1410112"},{"issue":"S1S","key":"719_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24875\/RMO.M21000206","volume":"95","author":"G Garc\u00eda-Aguirre","year":"2021","unstructured":"Garc\u00eda-Aguirre G, Garc\u00eda-Franco R, Fromow-Guerra J, Mira-Lorenzo X, Ram\u00edrez-Estudillo A, Jim\u00e9nez-Sierra JM, et al. Primer consenso Nacional de edema macular diab\u00e9tico. Revista Mexicana De Oftalmolog\u00eda. 2021;95(S1S):1\u20132.","journal-title":"Revista Mexicana De Oftalmolog\u00eda"},{"issue":"11","key":"719_CR46","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","volume":"132","author":"R Varma","year":"2014","unstructured":"Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, et al. Prevalence of and risk factors for diabetic macular edema in the united States. JAMA Ophthalmol. 2014;132(11):1334.","journal-title":"JAMA Ophthalmol"},{"key":"719_CR47","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Peralta L, Rivera-De la Parra D, Graue-Hern\u00e1ndez EO, Hern\u00e1ndez-Jim\u00e9nez S, Almeda-Vald\u00e9s P, Vel\u00e1zquez-Jurado H, et al. Discapacidad visual asociada a retinopat\u00eda diab\u00e9tica y edema macular: un estudio de base hospitalaria. Gac Med Mex. 2023;159(3).","DOI":"10.24875\/GMM.23000057"},{"issue":"10","key":"719_CR48","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ophtha.2021.03.010","volume":"128","author":"NA Malhotra","year":"2021","unstructured":"Malhotra NA, Greenlee TE, Iyer AI, Conti TF, Chen AX, Singh RP. Racial, ethnic, and Insurance-Based disparities upon initiation of Anti\u2013Vascular endothelial growth factor therapy for diabetic macular edema in the US. Ophthalmology. 2021;128(10):1438\u201347.","journal-title":"Ophthalmology"},{"issue":"2","key":"719_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1479164117746023","volume":"15","author":"YJ Peng","year":"2018","unstructured":"Peng YJ, Tsai MJ. Impact of metabolic control on macular thickness in diabetic macular oedema. Diab Vasc Dis Res. 2018;15(2):165\u20138.","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"719_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5301\/ejo.5000179","volume":"23","author":"TA Macky","year":"2013","unstructured":"Macky TA, Mahgoub MM. The effect of glycemic control on visual and anatomic outcomes in response to therapy for diabetic macular edema. Eur J Ophthalmol. 2013;23(1):94\u2013100.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"719_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jdiacomp.2013.11.009","volume":"28","author":"S Matsuda","year":"2014","unstructured":"Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166\u201370.","journal-title":"J Diabetes Complications"},{"issue":"8","key":"719_CR52","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ophtha.2015.04.029","volume":"122","author":"AS Bansal","year":"2015","unstructured":"Bansal AS, Khurana RN, Wieland MR, Wang PW, Van Everen SA, Tuomi L. Influence of glycosylated hemoglobin on the efficacy of Ranibizumab for diabetic macular edema. Ophthalmology. 2015;122(8):1573\u20139.","journal-title":"Ophthalmology"},{"issue":"12","key":"719_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.62.12.21","volume":"62","author":"MW Lee","year":"2021","unstructured":"Lee MW, Koo HM, Lee WH, Park JH, Lee YH, Kim JY. Impacts of systemic hypertension on the macular microvasculature in diabetic patients without clinical diabetic retinopathy. Invest Opthalmology Visual Sci. 2021;62(12):21.","journal-title":"Invest Opthalmology Visual Sci"},{"issue":"6","key":"719_CR54","doi-asserted-by":"publisher","first-page":"e16830","DOI":"10.1016\/j.heliyon.2023.e16830","volume":"9","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wu J, Wang Y, Wu J, Hu W, Jia H, et al. Associations between blood pressure levels and diabetic retinopathy in patients with diabetes mellitus: A population-based study. Heliyon. 2023;9(6):e16830.","journal-title":"Heliyon"},{"issue":"6","key":"719_CR55","doi-asserted-by":"publisher","first-page":"e0252321","DOI":"10.1371\/journal.pone.0252321","volume":"16","author":"C Busch","year":"2021","unstructured":"Busch C, Katzmann JL, Jochmann C, Unterlauft JD, Vollhardt D, Wiedemann P, et al. General health of patients with diabetic macular edema\u2014The LIPSIA study. PLoS ONE. 2021;16(6):e0252321.","journal-title":"PLoS ONE"},{"issue":"6","key":"719_CR56","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.xops.2024.100557","volume":"4","author":"R Haliyur","year":"2024","unstructured":"Haliyur R, Marwah S, Mittal S, Stein JD, Shah AR, Pershing S, et al. Demographic and metabolic risk factors associated with development of diabetic macular edema among persons with diabetes mellitus. Ophthalmol Sci. 2024;4(6):100557.","journal-title":"Ophthalmol Sci"},{"key":"719_CR57","doi-asserted-by":"crossref","unstructured":"Shah D, Dhamankar R, Shetty V, Haldipurkar S, Chipade P, Tanwar S, et al. Individual and combined effects of diabetes and glaucoma on total macular thickness and ganglion cell complex thickness: a cross-sectional analysis. J Ophthalmic Vis Res. 2022. https:\/\/kneopen.com\/jovr\/article\/view\/12303\/.","DOI":"10.18502\/jovr.v17i4.12303"},{"issue":"3","key":"719_CR58","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.apjo.2024.100067","volume":"13","author":"G Zhang","year":"2024","unstructured":"Zhang G, Chen W, Chen H, Lin J, Cen LP, Xie P, et al. Risk factors for diabetic retinopathy, diabetic macular edema, and sight-threatening diabetic retinopathy. Asia-Pacific J Ophthalmol. 2024;13(3):100067.","journal-title":"Asia-Pacific J Ophthalmol"},{"issue":"6","key":"719_CR59","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/pharmaceutics15061607","volume":"15","author":"T Mathis","year":"2023","unstructured":"Mathis T, El Ameen B, Vartin C, Serrar Y, Matonti F, Sudhalkar A, et al. Relevance of visual acuity measurement for therapeutic decisions in diabetic macular edema. Pharmaceutics. 2023;15(6):1607.","journal-title":"Pharmaceutics"},{"key":"719_CR60","doi-asserted-by":"publisher","first-page":"104042","DOI":"10.1016\/j.pdpdt.2024.104042","volume":"46","author":"P Viggiano","year":"2024","unstructured":"Viggiano P, Vujosevic S, Palumbo F, Grassi MO, Boscia G, Borrelli E, et al. Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy. Photodiagnosis Photodyn Ther. 2024;46:104042.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"719_CR61","doi-asserted-by":"publisher","unstructured":"Mukkamala L, Bhagat N, Zarbin MA. Practical lessons from Protocol I for the management of diabetic macular edema. In: Bandello F, Zarbin MA, Lattanzio R, Zucchiatti I, editors. Management of diabetic retinopathy. 2017. p. 91\u2013108. https:\/\/doi.org\/10.1159\/000459692.","DOI":"10.1159\/000459692"},{"key":"719_CR62","doi-asserted-by":"crossref","unstructured":"Kuo BL, Tabano D, Garmo V, Kim E, Leng T, Hatfield M, et al. Long-term treatment patterns for diabetic macular edema. Ophthalmol Retina. 2024.","DOI":"10.1016\/j.oret.2024.05.017"},{"issue":"4","key":"719_CR63","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.oret.2023.10.010","volume":"8","author":"P Emami-Naeini","year":"2024","unstructured":"Emami-Naeini P, Garmo V, Boucher N, Fernando R, Menezes A. Maintenance of vision needed to drive after intravitreal Anti-VEGF therapy in patients with neovascular Age-related macular degeneration and diabetic macular edema. Ophthalmol Retina. 2024;8(4):388\u201398.","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"719_CR64","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin AM, Chaya CJ, Kahook MY, Wirostko BM. Intraocular pressure elevation following intravitreal Anti-VEGF injections: Short- and Long-term considerations. J Glaucoma. 2021;30(12):1019\u201326.","journal-title":"J Glaucoma"},{"issue":"1","key":"719_CR65","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):13248.","journal-title":"Sci Rep"},{"issue":"5","key":"719_CR66","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/IAE.0000000000000520","volume":"35","author":"VS Dedania","year":"2015","unstructured":"Dedania VS, Bakri SJ, SUSTAINED ELEVATION OF INTRAOCULAR, PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS. Retina. 2015;35(5):841\u201358.","journal-title":"Retina"},{"issue":"8","key":"719_CR67","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","volume":"95","author":"TJ Good","year":"2011","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"719_CR68","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","volume":"85","author":"K Kotliar","year":"2007","unstructured":"Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and Biomechanical model. Acta Ophthalmol Scand. 2007;85(7):777\u201381.","journal-title":"Acta Ophthalmol Scand"},{"issue":"7","key":"719_CR69","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","volume":"28","author":"SJ Bakri","year":"2008","unstructured":"Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina. 2008;28(7):996\u20131001.","journal-title":"Retina"},{"issue":"2","key":"719_CR70","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1167\/iovs.10-6431","volume":"52","author":"L Liu","year":"2011","unstructured":"Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of Long-term storage and product mishandling. Invest Opthalmology Visual Sci. 2011;52(2):1023.","journal-title":"Invest Opthalmology Visual Sci"},{"issue":"3","key":"719_CR71","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000346397","volume":"229","author":"MN Menke","year":"2013","unstructured":"Menke MN, Salam A, Framme C, Wolf S. Long-Term intraocular pressure changes in patients with neovascular Age-Related macular degeneration treated with Ranibizumab. Ophthalmologica. 2013;229(3):168\u201372.","journal-title":"Ophthalmologica"},{"issue":"1","key":"719_CR72","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/jop.2014.0062","volume":"31","author":"AM Ricca","year":"2015","unstructured":"Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following Anti-Vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther. 2015;31(1):2\u201310.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"719_CR73","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/IJG.0000000000000173","volume":"25","author":"RG Morshedi","year":"2016","unstructured":"Morshedi RG, Ricca AM, Wirostko BM. Ocular hypertension following intravitreal antivascular endothelial growth factor therapy. J Glaucoma. 2016;25(3):291\u2013300.","journal-title":"J Glaucoma"},{"issue":"14","key":"719_CR74","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular Age-Related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"719_CR75","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular Age-Related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"719_CR76","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","volume":"121","author":"SJ Bakri","year":"2014","unstructured":"Bakri SJ, Moshfeghi DM, Francom S, Rundle AC, Reshef DS, Lee PP, et al. Intraocular pressure in eyes receiving monthly Ranibizumab in 2 pivotal Age-Related macular degeneration clinical trials. Ophthalmology. 2014;121(5):1102\u20138.","journal-title":"Ophthalmology"},{"issue":"6","key":"719_CR77","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating Ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064\u2013e107735.","journal-title":"Ophthalmology"},{"issue":"7","key":"719_CR78","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying G, shuang, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular Age-related macular degeneration. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"13","key":"719_CR79","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"Aflibercept","year":"2015","unstructured":"Aflibercept. Bevacizumab, or Ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203.","journal-title":"N Engl J Med"},{"key":"719_CR80","volume-title":"Cochrane database of systematic reviews","author":"L Moja","year":"2014","unstructured":"Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus Ranibizumab for neovascular age-related macular degeneration. In: Moja L, editor. Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014."},{"issue":"6","key":"719_CR81","doi-asserted-by":"publisher","first-page":"725","DOI":"10.21149\/12842","volume":"63","author":"AC Basto-Abreu","year":"2021","unstructured":"Basto-Abreu AC, L\u00f3pez-Olmedo N, Rojas-Mart\u00ednez R, Aguilar-Salinas CA, De la Cruz-G\u00f3ngora VV, Rivera-Dommarco J, et al. Prevalence of diabetes and glycemic control in mexico: National results from 2018 and 2020. Salud Publica Mex. 2021;63(6):725\u201333.","journal-title":"Salud Publica Mex"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00719-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:01:46Z","timestamp":1757329306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00719-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00719-9","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This protocol was conducted by the principles of the Declaration of Helsinki (1964), the ICH guidelines, and current local legislation. The study protocol and informed consent form were approved by their respective Institutional Review Boards, chosen by the research center or principal investigator as follows:\n                      Comit\u00e9 \u00c9tica en Investigaci\u00f3n del Instituto Mexicano de Trasplantes\n                      ,\n                      Comit\u00e9 de \u00c9tica en Investigaci\u00f3n de\n                      Medical Care and Research,\n                      Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Centro de Investigaci\u00f3n Cl\u00ednica Acelerada\n                      ,\n                      S.C\n                      ,\n                      Comit\u00e9 de \u00c9tica de Investigaci\u00f3n del Hospital de la Misi\u00f3n\n                      ,\n                      Comit\u00e9 de \u00c9tica en Investigaci\u00f3n de la Cl\u00ednica de Investigaci\u00f3n en Reumatolog\u00eda y Obesidad\n                      ,\n                      Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Hospital Christus Muguerza del Parque S.A de C.V\n                      ,\n                      Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed an informed consent form at the time of their inclusion and before any procedure was performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}